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Abstract. Oncolytic virotherapy has been emerging as a promising novel can-
cer treatment which may be further combined with the existing therapeutic
modalities to enhance their effects. To investigate how virotherapy could en-
hance chemotherapy, we propose an ODE based mathematical model describing
the interactions between tumour cells, the immune response, and a treatment
combination with chemotherapy and oncolytic viruses. Stability analysis of the
model with constant chemotherapy treatment rates shows that without any
form of treatment, a tumour would grow to its maximum size. It also demon-
strates that chemotherapy alone is capable of clearing tumour cells provided
that the drug efficacy is greater than the intrinsic tumour growth rate. Further-
more, virotherapy alone may not be able to clear tumour cells from body tissue
but would rather enhance chemotherapy if viruses with high viral potency are
used. To assess the combined effect of virotherapy and chemotherapy we use
the forward sensitivity index to perform a sensitivity analysis, with respect to
chemotherapy key parameters, of the virus basic reproductive number and the
tumour endemic equilibrium. The results from this sensitivity analysis indi-
cate the existence of a critical dose of chemotherapy above which no further
significant reduction in the tumour population can be observed. Numerical
simulations show that a successful combinational therapy of the chemothera-
peutic drugs and viruses depends mostly on the virus burst size, infection rate,
and the amount of drugs supplied. Optimal control analysis was performed, by
means of the Pontryagin’s maximum principle, to further refine predictions of
the model with constant treatment rates by accounting for the treatment costs
and sides effects. Results from this analysis suggest that the optimal drug and
virus combination correspond to half their maximum tolerated doses. This is
in agreement with the results from stability and sensitivity analyses.
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1. Introduction. Combination therapy strategies have shown significant promise
for treating cancers that are resistant to conventional modalities. Oncolytic vi-
rotherapy (OV) is an emerging treatment modality that uses replication competent
viruses to destroy cancers [22, 43, 27, 30]. Their tumour specific properties allow
for viral binding, entry, and replication [32]. Various studies have investigated com-
bination strategies with OV and chemotherapeutic drugs to optimize both viral
oncolysis and the effect of the added therapy [8, 32, 41]. Oncolytic viruses can
greatly enhance the cytotoxic mechanisms of chemotherapeutics [35]. Furthermore,
chemotherapeutic drugs lyse fast multiplying cells and, in general, virus infected
tumour cells quickly replicate [5]. In most combination studies with chemotherapy
drugs, apoptosis was increased but viral replication was not enhanced [32, 49, 3]. For
example, Nguyen et al. [32] gave an account of the mechanisms through which drugs
can successfully be used in a combination with oncolytic viruses. They, however,
noted that the success of this combination depended on several factors including the
type of oncolytic virus (OV)-drug combination used, the timing, frequency, dosage,
and cancer type targeted. A review of recent clinical studies by Binz and Urlrich
[8] shows the classification of possible combination of drugs and oncolytic viruses.
Oncolytic virotherapy is still ongoing clinical trials [49, 3], and some virus-drug com-
bos, for example talimogene laherparepvec, have been approved for the treatment
of melanoma [51].
While, there is a growing body of scientific research showing that combination
therapies are the cutting edge for cancer treatment, the design of an optimal proto-
col remains an open question. The chemo-viro therapy combination is no exception.
Despite a noticeable success in the clinical and experimental studies to investigate
and characterise the treatment of cancer with chemotherapeutics-virus combina-
tions, much is still not understood about chemovirotherapy. Some of the main
open questions in designing an optimal chemovirotherapy treatment are figuring
out the right dose combination, the most effective method of drug infusion, and the
important treatment characteristics [25].
Mathematical modelling and optimal control theory have over the years played
an important role in answering such important research questions which would cost
much to set up experimentally. Several mathematical studies including [15, 28, 37]
have addressed the dynamics of oncolytic virotherapy treatment. For example, Ur-
sher [50] gave a summary of some mathematical models for chemotherapy. Tian
[47] presented a mathematical model that incorporates burst size for oncolytic vi-
rotherapy. His analysis showed that there are two threshold burst size values and
below one of them the tumour always grows to its maximum size. His study af-
firmed that a tumour can be greatly reduced to low undetectable cell counts when
the burst size is large enough. A recent study by Malinzi et al. [29] showed that
that chemotherapy alone was not able to deplete tumour cells from body tissue but
rather in unison with oncolytic viruses could possibly reduce the tumour concen-
tration to a very low undetectable state. Other similar mathematical models on
virotherapy include [30, 53, 54, 33, 1].
In this paper, we address the question on: “what is the optimal chemothera-
peutic drug and virus dosage combination for the elimination of tumour cells in
body tissue?” To this end, we develop a mathematical model and optimal control
problem that account for the combination of cancer treatment using chemother-
apy and virotherapy. The paper is organised as follows. Section 2 is devoted to
the model description and the underlying assumptions. In Section 3, we analyse
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three sub-models: without-treatment model, chemotherapy-only model, and the
oncolytic virotherapy-only model. The analysis of the whole model, that is, the
chemotherapeutic drug combined with the virus therapy is detailed in Section 4.
In Section 5, we investigate an optimal control problem with a quadratic objective
function to determine the optimal dosage combination of the chemotherapy drug
and the virotherapy. The numerical simulations illustrating our theoretical results
are presented in Section 6. We conclude with a discussion in Section 7.
2. Model Formulation. In this section, we propose and formulate our new math-
ematical model describing the growth of an avascular solid tumour under the effect
of both chemotherapy and oncolytic virotherapy treatments. The model considers
six state variables summarized in Table 1. We first start by stating the underlying
model assumptions in Subsection 2.1, followed by the model equations and their
detailed description in Subsection 2.2.
2.1. Model description and assumptions. To model the effects of the chemo-
virotherapy on the tumour, we consider the dynamics of the following interacting
cell populations: tumour cells (both uninfected and virus-infected cells), immune
cells (both virus and tumour specific immune responses), the free virus and the
drug concentrations. Based on the discussion above and the scientific literature on
the interactions between the uninfected and the virus-infected tumour cells in the
presence of the oncolytic virotherapy and chemotherapy treatments, the following
assumptions are made in setting up the model:
1. Without treatment, the tumour grows logistically with a carrying capacity K
[47].
2. Virus infection, chemotherapeutic drug response to the tumour, chemokine
production and immune cells proliferation are considered to be of Michaelis–
Menten form to account for saturation [42, 2, 39].
3. The model accounts for both virus and tumour specific immune responses [21].
4. Virus production is a function of virus burst size and the death of infected
immune cells. The number of viruses therefore increases as infected tumour
cells density multiplies [47].
5. We consider both virus and tumour specific immune responses. Virus-specific
immune response is proportional to the infected tumour cell numbers whilst
the tumour specific immune response is taken to be of Michaelis–Menten form
to account for saturation in the immune proliferation [23].
6. We consider a case where drug infusion per day is constant. The constant in-
fusion rate may relate to a situation where a patient is put on an intravenous
injection or a protracted venous infusion and the drug is constantly pumped
into the body. This form of drug dissemination is used on cancer patients
who stay in the hospital for a long period of time. Higher doses of certain
anti-cancer drugs may however lead to hepatic veno-occlusive disease, a condi-
tion where the liver is obstructed as a result of using high-dose chemotherapy
[12, 55]. Another more realistic consideration would be to use periodic in-
fusion [7, 48]. This would lead to a periodic system of equations for which
standard theory on periodic systems applies (see for example [36]). This case
is, however, not dealt with in this work, and will be studied in a future work.
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2.2. Model equations. The proposed mathematical model consists of the follow-
ing system of six differential equations (1)–(6):
dU
dt
= αU
(
1− U + I
K
)
− βUV
Ku + U
− νUUET − δUUC
Kc + C
(1)
dI
dt
=
βUV
Ku + U
− δI − νIET I − τEV I − δIIC
Kc + C
(2)
dV
dt
= bδI − βUV
Ku + U
− γV (3)
dEV
dt
= φI − δVEV (4)
dET
dt
=
βT (U + I)
κ+ (U + I)
− δTET (5)
dC
dt
= g(t)− ψC (6)
The model variables and parameters, their meaning and base values are summarised
in Table 1 and Table 2 respectively.
Table 1. The model variables
Variable Description Units
U(t) Uninfected tumour density cells per mm3
I(t) Virus infected tumour cell density cells per mm3
V (t) Free virus particles virions per mm3
Ev(t) Virus specific immune response cells per mm
3
ET (t) Tumour specific immune response cells per mm
3
C(t) Drug concentration grams per millilitre (g/ml)
The initial conditions for the model are:
U(0) = U0, I(0) = I0, V (0) = V0, EV (0) = EV0 , ET (0) = ET0 , C(0) = C0, (7)
where the constants U0, I0, V0, EV0 , ET0 , and C0 denote the initial concentrations of
the uninfected tumour, virus infected tumour, free virus particles, virus specific im-
mune, tumour specific immune, and the chemotherapeutic drug respectively. They
are assumed to be nonnegative to make sense biologically. A detailed description
of the model follows.
In Eqs. (1) & (2), the terms αU
(
1− U+IK
)
represents tumour growth. The
term βUV/(Ku+U) describes infection of tumour cells by the virus where β is the
infection rate. Drug effect to the uninfected and infected tumour cells is respectively
described by the terms δUUC/(Kc + C) and δIIC/(Kc + C) where δU and δI are
lysis induced rates. Ku and Kc are Michaelis–Menten constants and relate to killing
rates when the virus and the drug are half-maximal [42, 2, 39]. The term νUUET
represents tumour specific immune response where νU is the uninfected lysis rate
by tumour specific immune cells. Infected tumour cells have a lifespan 1/δ and are
killed by both tumour and virus specific immune cells. These are described by the
terms νIET I and τEV I where δ is the natural death rate, νI and τ are respectively
lysis rates of tumour cells by the tumour specific and virus specific immune cells.
In Eq. (3), the term bδI represents virus proliferation where b is the virus burst
size and δ is the infected tumour cell death rate. The term βUV/(Ku+U) represents
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Table 2. The model parameters, their description and base values.
Symbol Description Value & units Ref.
K Tumour carrying capacity 106 cells per mm3 per day [4]
α Tumour growth rate 0.206 cells per mm3 per day [4]
β Infection rate of tumour cells 0.001− 0.1 cells per mm3 per day [4]
δ Infected tumour cells death 0.5115 day−1 [4]
γ Rate of virus decay 0.01 day−1 [4]
b Virus burst size 0− 1000 virions per mm3 per day [11]
ψ Rate drug decay 4.17 millilitres per mm3 per day [38]
δU Lysis rate of U by the drug 50 cells per mm
3 per day [38]
δI Lysis rate of I by the drug 60 cells per mm
3 per day [38]
φ EV production rate 0.7 day
−1 [9]
βT ET production rate 0.5 cells per mm
3 per day [18, 26]
δv, δT immune decay rates 0.01 day
−1 [18, 26]
Ku,Kc, κ Michaelis–Menten constants 10
5 cells per mm3 per day [24]
νU Lysis rate of U by ET 0.08 cells per mm
3 per day est
νI Lysis rate of I by ET 0.1 cells per mm
3 per day est
τ Lysis rate of I by EV 0.2 cells per mm
3 per day est
loss of free virus due to infection of the uninfected tumour cells. Virus deactivation
in body tissue is represented by the term γV where γ is the rate of decay.
In Eqs. (4) & (5), φI is the virus specific immune production and δvEv represents
its deactivation where δv is the decay rate. The term βT (U + I)/(k + (U + I))
represents tumour-specific immune response where βT is the rate of production and
k is a Michaelis constant. Tumour-specific immune decay is described by the term
δTET where δT is the rate of decay.
In Eq. (6), the time dependent function g(t) represents drug infusion into the
tumour and ψC describes drug decay where ψ is the rate of decay.
3. Mathematical analysis. To better understand the dynamics of the proposed
model, we begin by examining the model’s behaviour about the steady states. This
analysis is crucial for identifying the conditions necessary to achieve a tumour-
free state. We first show that the model is well posed in a biologically feasible
domain, and then proceed with a stability analysis of the model with constant drug
infusion. We then analyse the model in the case of no treatment, with chemotherapy
alone, and with oncolytic virotherapy alone. The case of the chemotherapeutic drug
combined with the virus therapy is detailed as well.
3.1. Well-posedness. Before we proceed with the mathematical analysis, we need
to show that the model is well posed in a biologically feasible domain. The model
describes the temporal evolution of cell populations, therefore, the cell densities
should remain non negative and bounded. The well-posedness theorem is stated
below and the proofs are given in Appendix A.
Theorem 3.1. (i) There exists a unique solution to the system of equations (1)–
(6) in the region D = (U, I, V, EV , ET , C) ∈ R6+.
(ii) If U(0) ≥ 0, I(0) ≥ 0, V (0) ≥ 0, EV (0) ≥ 0, ET (0) ≥ 0 and C(0) ≥ 0, then
U(t) ≥ 0, I(t) ≥ 0, V (t) ≥ 0, EV (t) ≥ 0, ET (t) ≥ 0 and C(t) ≥ 0 for all
t ≥ 0.
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(iii) The trajectories evolve in an attracting region Ω = {(U, I, V, EV , ET , C) ∈ D |
U(t)+I(t) ≤ K, V (t) ≤ b/γ, EV (t) ≤ φ/δV , ET ≤ βT /δT , C(t) ≤ C∗}, where
C∗ is the maximum drug concentration and depends on the infusion method.
(iv) The domain Ω is positive invariant for the model Equations (1)–(6) and there-
fore biologically meaningful for the cell concentrations.
We will analyse the model quantitative behaviour in the domain Ω.
3.2. Without-treatment model. To investigate the efficacy of each treatment,
their combination as well as the immune response to tumour cells, we first study
the model without any form of treatments. The model system of eqs. (1)–( 6)
without treatment reduces to the following system describing the interactions of
the uninfected tumour with the tumour specific immune cells:
dU
dt
= αU
(
1− U
K
)
− νUUET ,
dET
dt
=
βTU
κ+ U
− δTET . (8)
Proposition 1. The model (8) has two biologically meaningful steady states: a
tumour-free state, X1 = (U
∗ = 0, E∗T = 0), which is unstable and a tumour endemic
state,
X2 =
[
U
∗ =
K
2α
(
α−
ακ
K
−M
)
+
K
2α
√(
α−
ακ
K
−M
)2
+ 4
α2κ
K
, E
∗
T =
βT
δT
(
U∗
κ+ U∗
)]
,
(9)
where M = νUβT /δT , which is locally asymptotically stable.
Proof. Equating Eqs. (8) to zero yields:
α
K
U∗
2
+
(
ακ
K
+M − α
)
U∗ − ακ = 0 (10)
E∗T =
βT
δT
(
U∗
κ+ U∗
)
. (11)
From which if U∗ = 0 then E∗T = 0. The eigenvalues of the Jacobian matrix of
the model (8) evaluated at (0, 0) are λ1 = α and λ2 = −δT . One positive and the
other negative. Implying that the tumour free equilibrium is unstable. Compare
Equation (10) to aU∗
2
+ bU∗+ c = 0. We observe that c := −ακ < 0 implying that
∆ = b2 − 4ac :=
(
α − (ακK +M)
)2
+ 4α
2κ
K > 0 and therefore there is only one
positive root of the quadratic equation (10) and its given by
U∗ =
−b+√b2 − 4ac
2a
:=
K
2α
(
α− ακ
K
−M
)
+
K
2α
√(
α− ακ
K
−M
)2
+ 4
α2κ
K
.
The characteristic polynomial of the Jacobian matrix evaluated at X2 is given by
P (x) = x2 + P1x+ P0. (12)
We prove in Appendix B, using Routh–Hurwitz criterion, that P1 > 0 and P0 > 0
and thus the endemic steady state, X2, is locally asymptotically stable.
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Biological interpretation: Proposition 1 suggests that, without any form of treat-
ment, the tumour-free state is always unstable and the endemic state is stable im-
plying that the tumour would not be eliminated from the body.
Next, the model (1)–(6) is studied with only chemotherapy to investigate the
effect of the chemotherapeutic drug on tumour cells.
3.3. Chemotherapy-only model. We consider a case where drug infusion per
day is constant, that is, g(t) = q. The model with chemo-only, that is I = V =
EV = 0, reduces to:
dU
dt
= αU
(
1− U
K
)
− νUUET − δUUC
Kc + C
,
dET
dt
=
βTU
κ+ U
− δTET ,
dC
dt
= q − ψC. (13)
Proposition 2. The chemo-only model (13) has two biologically meaningful steady
states: a tumour-free sate, C1 = (U
∗ = 0, E∗T = 0, C
∗ = qψ ), which is stable if
αKu >
q(δU−α)
ψ and a tumour endemic state,
C2 =
[
U∗ =
K
2α
(
α−
(ακ
K
+ L+M
))
+
K
2α
√(
α−
(ακ
K
+ L+M
))2
+ 4
ακ
K
(α− L)
E∗T =
βT
δT
(
U∗
κ+ U∗
)
and C∗ =
q
ψ
]
, (14)
where
L =
δUC
∗
Kc + C∗
, M =
νUβT
δT
.
The endemic state, C2, is stable if the conditions (36) in Appendix B are satisfied.
Proof. Setting Equations in (13) to zero gives:
αU∗
(
1− U
∗
K
)
− νUU∗E∗T −
δUU
∗C∗
Kc + C∗
= 0, (15)
βTU
κ+ U∗
− δTE∗TU∗ = 0, C∗ =
q
ψ
, (16)
from which if U∗ = 0 then C1 = (U
∗ = 0, ET = 0, C
∗ = qψ ). The eigenvalues of the
Jacobian of (13) evaluated at C1 are λ1 = −ψ, λ2 = −δT and λ3 = α − δUq/ψKu+q/ψ
implying that for λ3 to be negative, then αKu >
q(δU−α)
ψ . If U
∗ 6= 0 then from
Equation (15),
E∗T =
βT
δT
(
U∗
κ+ U∗
)
and
α
K
U∗
2
+
(
ακ
K
+M + L− α
)
U∗ + κ(L− α) = 0
which when solved, and using the same analysis as in Proposition 1, gives the
expressions in Equation (14). The characteristic polynomial of the Jacobian matrix
evaluated at C2 is given in Equation (32). It directly follows from Routh–Hurwitz
criterion that the tumour endemic state, C2, is locally asymptotically stable if the
conditions (36) are fulfilled.
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Biological interpretation: Proposition 2 suggests that a tumour can be eradicated
by chemotherapy from the body tissue if the tumour growth rate is less than the
drug efficacy (α < δU ). Otherwise, it would continue to grow uncontrollably.
Since drug dosage, q, must not exceed the Maximum Tolerable Dose (MTD), de-
noted by qMTD, we further derive the following result in Proposition 3:
Proposition 3. 1. If δU < α, the tumour-free state will always be unstable for
any q < qMTD.
2. If δU > α:
(i) If qMTD < αψKuδU−α := q
∗, then the tumour-free state is unstable for all
q < qMTD.
(ii) If qMTD ≥ q∗, then the tumour-free state is locally asymptotically stable
for all q ∈ [q∗, qMTD].
Proof. 1. From the condition for stability in Proposition 2, if δU < α then αKu >
qψ
δU−α
, which violates the condition for stability.
2. If δU > α:
(i) If qMTD < αψKuδU−α := q
∗, yet the drug dosage, q, can not be larger than
the MTD, qMTD, implying that the condition for stability in Proposition
2 is still violated.
(ii) If qMTD > q∗, and q ∈ [q∗, qMTD] then the stability condition if fulfilled.
Biological interpretation: Proposition 3 suggests the followings:
1. For a chemotherapeutic drug that is not highly efficient (δU < α) the tumour
cannot be eradicated.
2. If the efficacy, δU , which is also the lysis rate measured in number of uninfected
tumour cells lysed per mm3 per day, is high enough but with:
(i) a very toxic drug, then one cannot give enough dose to eradicate the
tumour
(ii) a drug which is less toxic, then one can afford to give a dose which is not
larger than the MTD and yet which allows for the condition for stability.
3.4. Virotherapy-only model. To determine the effect of virotherapy on tumour
cells, we now study the model with only virotherapy treatment. The model (1)–(6)
with only virotherapy treatment, that is, C = 0, reduces to:
dU
dt
= αU
(
1− U + I
K
)
− βUV
Ku + U
− νUUET ,
dI
dt
=
βUV
Ku + U
− δI − νIET I − τEV I,
dV
dt
= bδI − βUV
Ku + U
− γV,
dEV
dt
= φI − δV EV ,
dET
dt
=
βT (U + I)
κ+ (U + I)
− δTET . (17)
Proposition 4. The virotherapy-only model (17) has three biologically meaningful
steady states: a tumour-free state V1 = (U
∗ = 0, I∗ = 0, V ∗ = 0, E∗T = 0, E
∗
V = 0)
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which is unstable, a virus-free state
V2 =
[
U∗ =
K
2α
(
α− ακ
K
−M
)
+
K
2α
√(
α− ακ
K
−M
)2
+ 4
α2κ
K
, I∗ = 0,
V ∗ = 0, E∗T =
βT
δT
(
U∗
κ+ U∗
)
, E∗V = 0
]
(18)
and a tumour endemic state V3 = (U
∗, I∗, V ∗, E∗T , E
∗
V ).
Proof. The above expressions are obtained when model equations in (17) are equated
to zero. The eigenvalues of the Jacobian matrix evaluated at V1 are λ1 = α,
λ2 = −δ, λ3 = −γ, λ4 = −δT and λ5 = −δV with one positive and the others
negative implying that the tumour-free state, V1, is unstable.
Biological interpretation: Proposition 4 suggests that virotherapy on its own is
not capable of eliminating tumour cells.
4. Chemovirotherapy. To assess the effects of the combination therapy of vi-
rotherapy and chemotherapy, we use the forward sensitivity index to perform a
sensitivity analysis of the virus basic reproductive number and the tumour endemic
equilibrium with respect to the chemotherapy key parameters. We now proceed to
study the whole model system (1)–(6) with constant drug infusion, that is, g(t) = q.
We first derive the model’s basic reproduction number, R0, and calculate its elas-
ticity indices with respect to the model parameters to identify which of them are
most sensitive during tumour infection. Finally, we calculate sensitivity indices of
the endemic total tumour density with respect to drug infusion.
4.1. Basic reproduction ratio. A basic reproductive number, in our case, can be
defined as the average number of new tumour infections generated by one infected
cell, via cell lysis, during virotherapy in a completely susceptible cell population
[52]. In general, if R0 > 1, then, on average, the number of new infections resulting
from one infected cell is greater than one. Thus, viral infections will persist in
tumour cell populations. If R0 < 1, then, on average, the number of new infections
generated by one infected cell in virotherapy is less than one. This implies that the
viral infections will eventually disappear from the cell populations. This threshold
can as well be used to depict parameters which are most important during tumour
infection. We calculate R0 using the next- generation matrix approach described in
[52]. Firstly, we prove that the conditions A1 −A5 in Appendix C are satisfied by
the model Equations (1)–(6).
Theorem 4.1. The basic reproduction ratio, R0, for constant drug infusion g(t) =
q, is given by
R0 =
bβδU∗(Kc + C
∗)
γ
[
(Kc + C∗)(νIE∗T + δ) + δIC
∗
](
Ku + U∗
) , (19)
where U∗, C∗ and E∗T are all given in Equation (14).
The proof of Theorem 4.1 can be found in Appendix C. Next, we calculate
elasticity indices of R0 in response to model parameters to ascertain which them
are most critical during chemovirotherapy treatment.
10 J. MALINZI, R. OUIFKI, A. ELADDADI, D.F.M. TORRES AND K.A.J. WHITE
Table 3. Sensitivity and elasticity indices of R0 with respect to
model parameters.
Parameter Sensitivity index Elasticity index
b Sb = 9.88 eb = 1
β Sβ = 988.4 eβ = 1
γ Sγ = −9884 eγ = −1
δ Sδ = 2.2325 eδ = 0.011553
α Sα = 2.4372 eα = 5.1× 10−12
δU SδU = −1.004× 10−7 eδU = −5.1× 10−12
δI SδI = −90.32 eδI = −0.011553
Kc SKc = 0.2048x eKc = 0.0000414
Ku SKu = −1.01× 10−6 eKu = −2.05× 10−10
ψ Sψ = 0.004 eψ = 0.000414
q Sq = −0.008 eq = −0.000414
4.2. Sensitivity of the basic reproduction ratio.
Definition 4.2. The Sensitivity and elasticity indices of the basic reproduction
ratio, R0, with respect to model parameter p are respectively given by Sp =
∂R0
∂p
and ep =
∂R0
∂p
p
R .
Table 3 shows the sensitivity and elasticity indices obtained with the use of Sage.
From the Table one can note that a 1% increase in virus burst size, b, and infection
rate, β, leads to a 1% increase in R0, whereas a 1% increase in the virus decay rate,
γ, leads to a 1% reduction in R0. The indices indicate that R0 is most sensitive to
virus burst size, infection and decay rates. Figure 1 is a graphical representation of
the indices. Figure 2 (a) shows the variation of elasticity of R0 with respect to drug
dosage. The figure indicates that increasing the amount of drug infused reduces R0
and thus reduces the number of tumour cells. From the figure we can further infer
that values of the drug dosage, q, from 40 mg/l to 100 mg/l have a less significant
impact on R0.
4.3. Sensitivity of endemic equilibria. Sensitivity indices of the endemic equi-
libria is informative about the establishment of the disease. Here, we calculate
sensitivity indices of the endemic total tumour density with respect to drug infu-
sion. The gist is to determine the relative change in the tumour equilibria when the
amount of drug infused is changed and thus infer the feasible amount of the drug
that should be infused. The sensitivity index of the total tumour endemic equilibria
U∗ + I∗ with response to drug infusion q is given by
ΓU
∗+I∗
q =
∂(U∗ + I∗)
∂q
· q
U∗ + I∗
=
U∗
U∗ + I∗
ΓU
∗
+
I∗
U∗ + I∗
ΓI
∗
. (20)
where ΓU
∗
and ΓI
∗
are calculated from the formula in Equation (41) derived in
Appendix D. It is worth noting that the endemic equilibrium of the full chemother-
apy model (1)–(6) can not explicitly be determined in terms of the parameters and
therefore we numerically computed the equilibrium values.
We used high values of the tumour reproduction rate and virus burst size, that is
α = 0.8 cells/mm3/day and b = 50 virions/mm3/day so that R0 > 1. We calculated
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Table 4. Selected sensitivity indices of the total tumour equilibria,
ΓU+Ip , in response to drug , q with the corresponding value of R0.
q (mg/l) 5 10 15 35 50 100
ΓU
∗+I∗
p −8.3× 10−5 −2.5× 10−5 −1× 10−5 −6.1× 10−5 −9.6× 10−6 −2.4× 10−6
R0 51.0476 51.0473 51.0470 51.0459 51.0450 51.0421
ΓU
∗+I∗ for several values of q. Table 4 shows selected indices for different amounts
of the drug infused with their corresponding basic reproduction ratios. Figure 2 (b)
is a plot of total tumour sensitivity index with respect to drug infusion. The figure
suggests that the feasible amount of drug that should be infused in a patient lies
between 50 mg/l and 100 mg/l. This range of values is similar to those inferred
from the elasticity indices of R0.
It is worth noting that when q becomes larger than 50 mg/l, the impact of
chemotherapy on virotherapy (R0 and endemic equilibria) becomes less significant.
This analysis, nonetheless, does not incorporate the cost for example monetary or
treatments side effects. These results will further be confirmed using optimal control
theory. In the next section, we set up an optimal control problem to explicitly deter-
mine the optimal virus and chemotherapeutic drug dosage combination necessary
for tumour eradication in body tissue.
5. Optimal control analysis. In this section, we propose and analyze an optimal
control problem applied to the chemovirotherapy model to determine the optimal
dosage combination of chemotherapy and virotherapy for controlling the tumour.
We set the control variables u1(t) and u2(t) ≡ g(t) to respectively be the supply of
viruses from an external source of the drug dosage, which are then incorporated into
the model system’s equations (3) and (6) to obtain the following control system.
For model tractability, we ignore the immune responses.
dU
dt
= αU
(
1− U + I
K
)
− βUV
Ku + U
− δUUC
Kc + C
dI
dt
=
βUV
Ku + U
− δI − δIIC
Kc + C
dV
dt
= bδI − βUV
Ku + U
− γV + u1(t)
dC
dt
= u2(t)− ψC (21)
5.1. The optimal control problem. We wish to determine the optimal combi-
nation of controls (u1(t), u2(t)) that will be adequate to minimize the total tumour
density (U(t) + I(t)) together with the cost of the treatment and negative side ef-
fects over a fixed time period. The optimization problem under consideration is to
minimise the objective functional:
J(u1, u2) =
∫ Tf
0
[
U(t) + I(t) +
(
A1
2
u21(t) +
A2
2
u22(t)
)]
dt (22)
where Tf is the termination time of the treatment, subject to the control system
(21). The two control functions u1(t) and u2(t) are assumed to be bounded and
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Lebesgue integrable. We thus seek an optimal control pair (u∗1, u
∗
2) such that:
J(u∗1, u
∗
2) = min
{
J(u1, u2)|(u1, u2) ∈ Λ
}
(23)
where Λ is the control set defined by:
Λ =
{
(u1, u2)|ui is measurable with 0 ≤ ui(t) ≤ uMTDi , t ∈ [0, Tf ], i = 1, 2
}
where uMTD1 is the maximum number of viruses body tissue can contain and u
MTD
2
is the maximum tolerated drug dose. These may as well be viewed as the maximum
amounts a patient can financially afford. The lower bounds for u1 and u2 correspond
to no treatment. Here, it is important to note that the balancing factors A1 and A2
in the objective functional (22) are the relative measures of both the cost required
to implement each of the associated controls as well as the negative sides effects due
to the treatment.
5.2. Existence of an optimal control pair. We examine sufficient conditions
for the existence of a solution to the quadratic optimal control problem.
Proposition 5. There exists an optimal control pair (u∗1, u
∗
2) with a corresponding
solution (U∗, I∗, V ∗, C∗) to the model system (21) that minimizes J(u1, u2) over
Λ.
Proof. The proof of Proposition 5 is based on Theorem 4.1 in Chapter III of Fleming
and Rishel [16]. The necessary conditions for existence are stated and verified as
follows.
(1) The set of all solutions to the control system (21) and its associated initial
conditions and the corresponding control functions in Λ is non-empty.
(2) The control system can be written as a linear function of the control variables
with coefficients dependent on time and state variables.
(3) The integrand in the objective functional in Equation (21) is convex on Λ.
The right hand sides of the control system (21) are C1 and bounded below and
above (see Appendix A), thus the solutions to the state equations are bounded. It
therefore follows from the Picard–Lindelo¨f theorem [44] that the system is Lipschitz
with respect to the state variables. Thus, condition (1) holds. It can be seen from
the control system (21) that the right hand sides are linearly dependent of u1 and
u2. Thus, condition (2) also holds. To establish condition (3), we notice that the
integrand L in the objective functional (21) is convex because it is quadratic in the
controls.
5.3. Optimal control characterization. In this section, we characterize the op-
timal controls u∗ = (u∗1, u
∗
2) which gives the optimal levels for the various control
measures and the corresponding states (U∗, I∗, V ∗, C∗). The necessary conditions
for the optimal controls are obtained using the Pontryagin’s Maximum Principle
[40]. This principle converts the model system (21) into a problem of minimizing
pointwise a Hamiltonian, H, with respect to u1 and u2 as detailed below.
Proposition 6. Let T = (U, I, V, C) and u = (u1, u2). If (T
∗(t), u∗(t)) is an
optimal control pair, then there exists a non-trivial vector
λ(t) = (λ1(t), λ2(t), · · ·λ4(t))
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satisfying the following:
λ′1(t) = −1− λ1
[
α
(
1− 2U + I
K
)
− βKuV
(Ku + U)2
− δUC
Kc + C
]
,
− λ2
[
βKuV
(Ku + U)2
]
+ λ3
[
βKuV
(Ku + U)2
]
,
λ′2(t) = −1− λ1
[
αU
K
]
+ λ2
[
δ +
δIC
Kc + C
]
− λ3bδ,
λ′3(t) = λ1
[
βU
Ku + U
]
− λ2
[
βU
Ku + U
]
+ λ3
[
βU
Ku + U
+ γ
]
,
λ′4(t) = λ1
[
KcδuU
(Kc + C)2
]
+ λ2
[
KcδII
(Kc + C)2
]
+ λ4ψ,
(24)
with transversality conditions
λi(Tf ) = 0, i = 1, 2, · · · 4. (25)
and optimal controls:
u∗1 = min
[
uMTD1 ,max
(
0,− λ3
A1
)]
, u∗2 = min
[
uMTD2 ,max
(
0,− λ4
A2
)]
. (26)
Proof. The Lagrangian and Hamiltonian for the optimal control system (21) are
respectively given by:
L(U, I, V, C, u1, u2) = U + I + 1
2
[
A1u
2
1 +A2u
2
2
]
(27)
and
H = U + I + 1
2
[
A1u
2
1 +A2u
2
2
]
+ λ1
[
αU
(
1− U + I
K
)
− βUV
Ku + U
− δUUC
Kc + C
]
+ λ2
[
βUV
Ku + U
− δI − δIIC
Kc + C
]
+ λ3
[
bδI − βUV
Ku + U
− γV + u1
]
+ λ4
[
u2 − ψC
]
.
(28)
We thus obtain Equation (24) using the Pontryagin’s maximum principle from
λ′(t) = −∂H
∂T
(
t, T ∗(t), u∗(t), λ(t)
)
. (29)
The transversality conditions are as given in Equation (25) since all states are free
at Tf . The Hamiltonian is maximized with respect to the controls at the optimal
control u∗ = (u∗1, u
∗
2). Therefore H is differentiated with respect to u1 and u2 on Λ,
respectively, to obtain
0 =
∂H
∂u1
= A1u1 + λ3,
0 =
∂H
∂u2
= A2u2 + λ4.
Thus, solving for u∗1 and u
∗
2 on the interior sets gives
u∗1 = −
λ3
A1
, u∗2 = −
λ4
A2
.
14 J. MALINZI, R. OUIFKI, A. ELADDADI, D.F.M. TORRES AND K.A.J. WHITE
By standard control arguments involving the bounds on the controls, 0 ≤ u1(t) ≤
uMTD1 , 0 ≤ u2(t) ≤ uMTD2 , we conclude that:
u∗1 = min
[
uMTD1 ,max
(
0,− λ3
A1
)]
, u∗2 = min
[
uMTD2 ,max
(
0,− λ4
A2
)]
. (30)
5.4. The optimality system. In summary, the optimality system consists of the
control system (21) and the adjoint system (24) with its transversality conditions
25, coupled with the control characterizations (30). Next, we proceed to solve
numerically the proposed model and the optimal control problem.
6. Numerical simulations. In this section, we discuss the numerical solutions
of both the chemovirotherapy model equations (1)–(6) and the optimal control
problem defined in Section 5.4. We also outline the parameter choices and the
initial conditions. We use parameter values in Table 2 to solve model equations
and the optimality system. The numerical solutions of the model equations are
illustrated using MATLAB, while the optimality system was solved using a fourth
order Runge–Kutta iterative method.
6.1. Parameter values and initial conditions. Some of the parameter values
were obtained from fitted experimental data for untreated tumours and virotherapy
in mice [4] and others from biological facts in the literature. A tumour nodule
can contain about 105 − 109 tumour cells [45]. The carrying capacity is therefore
considered to be 106 cells per mm3. In vivo experiments estimate the intrinsic rate
of growth to be 0.1 − 0.8 day−1 [6]. We consider the number of viruses produced
per day, b, to be in the range 0− 1000 virions [11]. The amount of drug infused in
body tissue, q, is considered to be 5 milligrams per day and the decay rate, ψ, to be
4.17 milligrams per day, values which conform to cancer pharmacokinetic studies
[10, 34]. Since infected tumour cells multiplication is enhanced by the oncolytic
virus replication, the tumour cells lysis, δI , is considered to be greater than that for
uninfected tumour cells δU (see Ref [38]). We considered a virus-specific immune
response rate, φ, of 0.7 day−1 [9]. Both virus and tumour specific immune decay
rates are assumed to be 0.01 day−1, given the fact that their lifespan is less than 100
days [26, 31]. The tumour-specific production rate was estimated at 0.5 cells per
mm3 per day [18, 26]. In all our simulations, unless stated otherwise, we considered
the initial concentrations U0 = 10000 cells per mm
3, I0 = 100 cells per mm
3,
V0 = 500 virions per mm
3, Ev0 = 100 cells per mm
3, ET0 = 100 cells per mm
3 and
C0 = 100 g/ml with a high percentage of untreated tumour cell count to require
treatment.
6.2. Chemovirotherapy model. Figures 3 (a)&(b) are respectively plots of the
uninfected tumour density for different virus and drug doses. Both figures depict
that an increase in the virus burst size (b) and drug dose (q) reduces the tumour
density. In Figure 3 (a), without virotherapy, that is b = 0 virions, the tumour is
depleted in about 10 days whereas without chemotherapy, that is q = 0 milligrams
per day, it takes about 20 days.
Figures 4 and 5 (a)&(b) respectively show the effect of virus burst size on the
virus and infected tumour cell densities. Both figures show that the densities with
increasing burst size and infection rate. From Figure, for example 4, an increase
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Figure 1. Visual representation of the elasticity indices ofR0 with
respect to model parameters. The bar graph shows that the virus
burst size, infection and decay rates b, β & γ have the highest
elasticity indices with virus decay being negatively correlated to
R0.
of b from 250 to 500 virions led to an increase of the virus number to about 700
virions from 500 virions, in the first 100 days.
Figure 5 (a)&(b) show that increasing virus infection rate, β, reduces the virus
density and increases the infected tumour density. For example from Figure 5 (a),
an increase in β from 0 to 1 cells per mm3 per day led to a reduction by about 100
viruses from 120 whereas it led to an increase by about 10 viruses in the first day,
from 0 as seen in Figure 5 (b).
16 J. MALINZI, R. OUIFKI, A. ELADDADI, D.F.M. TORRES AND K.A.J. WHITE
(a)
(b)
Figure 2. Plots of the elasticity indices, eq, and Γ
U∗+I∗
q against
the drug dosage q. Both Figures (a) and (b) depict that increasing
the amount of drug infused reduces viral multiplication thus reduc-
ing the sensitivity indices. The figures further suggest that values
of q from 40 to 100 mg/l have minimal negative impact on viral
replication.
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Figure 3. (a) Plots of uninfected cell density with constant drug
infusion and for different virus burst sizes. The plot shows that
an increase in the virus burst size reduces the tumour density. (b)
Plots of uninfected cell density with constant drug infusion and for
different drug infusion rates. The plot shows that an increase in
the drug infusion rate reduces the tumour density by a relatively
small magnitude.
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Figure 4. Plots of the virus and infected tumour densities for dif-
ferent virus burst size. The plots show that both densities increase
with increasing virus burst size.
6.3. Optimal control problem. Figure 6 is a plot of total tumour density of
the optimal control solution to the problem formulated in Section 5. It shows the
tumour density being reduced by the combinational therapy treatment to a very
low state in less than a week.
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Figure 5. (a) Plots of the virus density for different virus infection
rate. The plots show the virus density reduces with increasing virus
infection rates. (b) Plots of infected tumour density for different
infection rates. The figure shows that the infected tumour density
increases as the infection rate increases.
Figures 7 (a)&(b) represent the optimal controls u1 and u2. The figures suggest
that the optimal values of the number of viruses and drug concentration that yields
efficient combination therapy are half their maximal dosages uMTD1 and u
MTD
2 .
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Figure 6. Total tumour density with optimal control. The tu-
mour density is reduced in a very short time period.
7. Conclusion. Successful cancer treatment often requires a combination of treat-
ment regimens. Recently, combined oncolytic virotherapy and chemotherapy has
been emerging as a promising, effective and synergetic cancer treatment. In this
paper we consider a combination therapy with chemotherapy and virotherapy to in-
vestigate how virotherapy could enhance chemotherapy. To this end, we developed
a mathematical model and an optimal control problem to determine the optimal
chemo-virus combination to eradicate a tumour. We firstly validated the model’s
plausibility by proving existence, positivity and boundedness of the solutions. We
analysed the model in four scenarios: without treatment, with chemotherapy, with
oncolytic virotherapy alone, and with combined chemotherapeutic drug and virus
therapy. A basic reproduction number for the infection of the tumour cells was
calculated to analyse the model’s tumour endemic equilibrium. Furthermore, sensi-
tivity and elasticity indices of the basic reproduction number and tumour endemic
equilibria with respect to drug infusion were calculated. The optimal control prob-
lem was solved using the Pontryagin’s Maximum Principle. Numerical solutions to
the proposed model were carried out to illustrate the analysis results. Similarly,
numerical solutions to the optimal control problem were carried out to identify
the optimal dosages for the minimization of the chemo-virus combination. Model
analysis and simulations suggest the following results.
The stability analysis showed that a tumour can grow to its maximum size in a
case where there is no treatment. It also demonstrated that chemotherapy alone
is capable of clearing tumour cells provided that the drug efficacy is greater than
the intrinsic tumour growth rate. This can be evidenced in a study by Dasari and
Tchounwou [14] and references therein. Furthermore, the result emphasised that if
the chemotherapeutic drug’s efficacy is high enough but with a toxic drug then the
tumour cannot be eliminated. If, however, the drug is not toxic, then a dosage which
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Figure 7. Optimal control variable variables u1: The external
supply of viruses and u2: Drug dosage. The Figures depict 500
virions as the optimal number of viruses and the optimal drug
dosage to be 50 m/g per.
is not larger than the maximum tolerated dose can be given while still allowing for
a stability condition of the tumour free equilibrium, thus eliminating the tumour.
In the case of virotherapy alone, stability analysis revealed that virotherapy
on its own may not clear tumour cells but rather highly enhances chemotherapy
in destroying tumour cells. Several clinical and experimental studies for example
[35, 8, 20, 41] confirm this result. In a review of clinical studies by Binz and Ulrich
[8], it is stated that phase II/III clinical trials on combining adenovirus H101 with
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a chemotherapeutic drug, cisplatin and 5-fluorouracil, leads to a 40% improvement
compared to chemotherapy alone for the treatment of patients with head and neck
cancer. Adenovirus Ad-H101 was consequently approved for the treatment of head
and neck cancers in China and recently in the United states after phase III clinical
trials showed a 72–79% response rate for the combination of the virus with 5-
fluorouracil compared to a 40% with chemotherapy alone [19].
Sensitivity analysis and elasticity indices of the basic reproduction ratio indicated
that successful chemovirotherapy is highly dependent on the virus burst size and its
infection rate as well as on the drug infusion and its decay rates. Larger virus burst
size and higher replication rates lead to a lower tumour concentration. Whereas,
low decay and high doses of the drug that the body can tolerate lead to better treat-
ment results. Sensitivity analysis of both the basic reproduction ratio and model
equilibria suggested the feasible drug infusion to be between 50 and 100 milligrams
per litre. The effect of virus burst size and infection rates in determining the success
of virotherapy have extensively been confirmed in recent mathematical studies (see
for example [29, 47, 13]). Nonetheless, the right dose of chemotherapy treatment
has always been a question and a concern to both clinicians and mathematicians
alike [25, 17]. In this study, optimal control results further indicated that 50% of the
maximum drug and virus tolerated dosages (MTDs) optimize chemovirotherapy.
In addition, numerical simulations suggested that with the use of both chemother-
apy and virotherapy, a tumour may be eradicated in less than a month. We know
that this is not realistic for human cancers and is strictly based on the experimental
data used in the numerics. Simulations further showed that a successful combina-
tional therapy of cancer drugs and viruses is mostly dependent on virus burst size,
infection rate and the amount of drugs supplied into a patient’s body which is in
agreement with recent studies [29, 47, 13].
The mathematical model we developed in this study is a simple one, for example,
it considers the cell densities to only be time dependent. It is therefore imperative
for further studies to incorporate more biological aspects like spatial variation of the
cell concentrations. Another facet would be to investigate the effect of toxicity of
both viruses and the drug on normal body tissue. The key to improving combined
virotherapy and chemotherapy lies in quantifying the dependence of treatment out-
come on immune stimulation. Another extension to this model, would be to include
other subpopulations of the immune system. Nevertheless, the results here empha-
sise the treatment characteristics that are vital in combining drugs and viruses to
treat cancer and an optimal drug and virus dosage is suggested.
Appendices
A. Appendix A.
A.1. Proof of Theorem 3.1(i) on the existence and uniqueness of model solutions
Proof. The functions on the right hand side of Equations (1)–(6) are C1 on Rn.
Thus, it follows from the Picard–Lindelo¨f theorem (see [44]) that (1)–(6) exhibit a
unique solution.
A.2. Proof of Theorem 3.1(ii)&(iii) on positivity and boundedness
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Proof. The solution to Equation (6) is given by
C(t) = exp(−ψt)
(∫ t
0
g(s) exp(ψs)ds+ C(0)
)
≥ 0.
Let the model equations (1)-(5) be written in the form x′ = F (t, x). The functions
F (x, t) on the right hand side of Equations (1)–(5) have the property of
F (U, I, V, EV , ET , t) ≥ 0 whenever x ∈ [0,∞)n, xj = 0, t ≥ 0,
where x = (U, I, V, EV , ET ). Thus, it follows from Proposition A.1 in [46] that
x(t) ∈ [0,∞)n for all t ≥ t0 ≥ 0 whenever x(t0) ≥ 0
and thus the model solutions x = (U, I, V, EV , ET ) are positive and bounded for
positive initial values x0.
A.3. Proof of Theorem 3.1(iv) on positive invariance
Proof. The proof directly follows from proofs of Theorems 3.1 (i)–(iii).
B. Appendix B.
B.1. Proof of stability of tumour endemic state, X2, in Proposition 1.
Proof. Denote U∗ := Up + Ur where
Up = − b
2a
=
K
2α
(
α− ακ
K
−M
)
,
Ur =
√
b2 − 4ac
2a
=
K
2α
√(
α− ακ
K
−M
)2
+ 4
α2κ
K
.
The characteristic polynomial of the Jacobian matrix evaluated at X2 is given by
P (x) = x2 + P1x+ P0 (31)
where P0 = P01U
∗ + P00 and P1 = P11U
∗ + P10,
P00 = Kκ (α δT K − βT νuK + ακ δT ) ,
P01 =
K
(
K(αδT − βT νU )2 + κ δT 2α2 + αβT κ νu δT
)
α δT
,
P10 = KκδT (α+ δT ) ,
P11 = K
(
α δT − βT νu + δT 2
)
.
Using Routh–Hurwitz criterion, the endemic steady state, X2, is locally asymptot-
ically stable if P1 > 0 and P0 > 0.
We notice that P01 > 0. This means that P0 > 0 if and only if U
∗ > −P00/P01
which is equivalent to
Ur > −P00
P01
− Up ⇔ U2r −
(
P00
P01
+ Up
)2
> 0.
With the help of MapleR©, we find that
U2r −
(
P00
P01
+ Up
)2
= αβT κ
2νu δT
(
K2(αδT − βT νU )2 + 2KκδT 2α2
+ 2KαβT κ νu δT + α
2κ2δT
2
)
> 0.
Therefore P0 > 0.
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For P1, we discuss the following cases:
(i) If P11 > 0 then P1 > 0.
(ii) If P11 < 0 then P1 > 0 if and only if U
∗ < −P10/P11 which is equivalent to
U2r −
(
P10
P11
+ Up
)2
< 0.
Using MapleR©, we find that
U2r −
(
P10
P11
+ Up
)2
= βT κ νu δT
(
K(α δT − βT νu + δT 2)− ακ(α + δT )
)
< 0.
This implies that P1 > 0.
Therefore the endemic steady state, X2, is locally asymptotically stable.
B.2. Proof of stability of endemic state, C2, in Proposition 2
Proof. The characteristic polynomial, P (x), of the Jacobian evaluated at C2 is given
by
P (x) = x3 +
(
2Uα
K
− α+ δT +
CδU
C +Kc
+
UβT νU
(U + κ)δT
+ ψ
)
x
2 (32)
+
(
2UαδT
K
− αδT +
CδT δU
C +Kc
+
2UβT νU
U + κ
−
U2βT νU
(U + κ)2
(33)
+
2Uαψ
K
− αψ + δTψ +
CδUψ
C +Kc
+
UβT νUψ
(U + κ)δT
)
x (34)
+
2UαδTψ
K
− αδTψ +
CδT δUψ
C +Kc
+
2UβT νUψ
U + κ
−
U2βT νUψ
(U + κ)2
= 0. (35)
The conditions for stability of the endemic state, C2, therefore follow from the
Routh–Hurwitz criterion and are stated as:
a2 : =
2U∗α
K
− α+ δT + C
∗δU
C∗ +Kc
+
U∗βT νU
(U∗ + κ)δT
+ ψ > 0,
a1 : =
2U∗αδT
K
− αδT + C
∗δT δU
C∗ +Kc
+
2U∗βT νU
U∗ + κ
− U
∗2βT νU
(U∗ + κ)
2
+
2Uαψ
K
− αψ + δTψ + C
∗δUψ
C∗ +Kc
+
U∗βT νUψ
(U∗ + κ)δT
> 0,
a0 :=
2U∗αδTψ
K
− αδTψ + C
∗δT δUψ
C∗ +Kc
+
2U∗βT νUψ
U∗ + κ
− U
∗2βT νUψ
(U∗ + κ)
2 > 0 and a2a1 > a0.
(36)
C. Appendix C.
C.1. Proof of conditions A1 −A5 for the derivation of R0
Proof. Denote x = (x1, x2, · · ·x5)T = (U, I, V, EV , ET )T with xi ≥ 0 be the set
of cell compartments divided into infected cells i = 1, · · · ,m and uninfected cells
i = m+ 1, · · · , n. Define X0 to be the set of virus or infection free states:
X0 := {x ≥ 0 : xi0, for all i = 1, · · · ,m}.
Let Fi(t, x) be the input rate of newly infected cells in the ith compartment. Let
V+i (t, x) and V−i (t, x) respectively be the input rate of cells by other means and rate
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of transfer of cells out of a compartment i. Thus the system of Equations (1)–(6)
take the form
dxi
dt
= Fi(t, x) − Vi(t, x).
We now proceed to prove the assumptions A1 −A5:
A1: For each 1 ≤ i ≤ n, the functions Fi(t, x), V+i and V−i are non-negative
and continuous on R×Rn+ and continuously differentiable with respect to x. From
Equations (1)–(6)
Fi =
(
βUV
Ku+U
0
)
, V+i =
(
δI + νIET I +
δIIC
Kc+C
γv
)
, V−i =
(
τEV EV I
bδ
)
.
(37)
Clearly, Fi, V〉+i and V−i satisfy A1.
A2: If xi = 0, then Vi = 0. Clearly, from (37), if the state variables are all equal
to zero, then Vi = 0.
A3: Fi = 0 for i > m. This can be seen from the compartments U , EV and ET .
A4: If x ∈ X0 , then Fi(x) = V+i (x) = 0 for i = 1, · · · ,m. At X0, V and I are
zero, implying that Fi = V+i = 0.
A5: If Fi = 0, then all the eigenvalues of DV(X0) have positive real parts. This
can be ascertained from Equation (37).
C.2. Proof of Theorem 4.1
Proof. From Equation (37),
F =
(
0 βUKu+U
0 0
)
, V =
(
δ + νIET +
δIC
∗
Kc+C
+ τEv 0
bδ γ
)
,
FV −1 =
1
γ(δ + νIE∗T +
δIC∗
Kc+C∗
)
(
bδβU
KU+U
bβU∗
(Ku+U∗)
0 0
)
.
Thus
R0 = ρ(FV
−1) =
bβδU∗(Kc + C
∗)
γ
[
(Kc + C∗)(νIE∗T + δ) + δIC
∗
](
Ku + U∗
) . (38)
D. Appendix D.
D.1. Elasticity indices of R0
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eb = 1
eβ = 1
eγ = −1
eδ = −
Γ1 (KKcαψ +KcKuαψ +Kαq +Kuαq −KδUq)(Kcδψ + δq + δIq)γ
(Kcαψ + αq − δU q)(Kcψ + q)Kbβ
eα = −
Γ2 (KKcαψ +KcKuαψ +Kαq +Kuαq −KδUq)(Kcδψ + δq + δIq)αγ
(Kcαψ + αq − δU q)(Kcψ + q)Kbβδ
eδU =
Γ3 (KKcαψ +KcKuαψ +Kαq +Kuαq −KδUq)(Kcδψ + δq + δIq)δUγ
(Kcαψ + αq − δUq)(Kcψ + q)Kbβδ
eδI = −
δIq
Kcδψ + δq + δIq
eKc =
Γ4Kcψq
(KKcαψ +KcKuαψ +Kαq +Kuαq −KδUq)(Kcαψ + αq − δU q)(Kcδψ + δq + δIq)(Kcψ + q)
eKu = −
(Kcψ + q)Kuα
KKcαψ +KcKuαψ +Kαq +Kuαq −KδUq
eψ =
Γ4Kcψq
(KKcαψ +KcKuαψ +Kαq +Kuαq −KδUq)(Kcαψ + αq − δU q)(Kcδψ + δq + δIq)(Kcψ + q)
eq = −
Γ4Kcψq
(KKcαψ +KcKuαψ +Kαq +Kuαq −KδUq)(Kcαψ + αq − δU q)(Kcδψ + δq + δIq)(Kcψ + q)
,
(39)
where
Γ1 =
(Kcαψ + αq − δUq)(Kcψ + q)2Kbβδ
(KKcαψ +KcKuαψ +Kαq +Kuαq −KδUq)(Kcδψ + δq + δIq)2γ
− (Kcαψ + αq − δUq)(Kcψ + q)Kbβ
(KKcαψ +KcKuαψ +Kαq +Kuαq −KδUq)(Kcδψ + δq + δIq)γ
Γ2 =
(KKcψ +KcKuψ +Kq +Kuq)(Kcαψ + αq − δUq)(Kcψ + q)Kbβδ
(KKcαψ +KcKuαψ +Kαq +Kuαq −KδUq)2(Kcδψ + δq + δIq)γ
− (Kcψ + q)
2Kbβδ
(KKcαψ +KcKuαψ +Kαq +Kuαq −KδUq)(Kcδψ + δq + δIq)γ
Γ3 =
(Kcαψ + αq − δUq)(Kcψ + q)K2bβδq
(KKcαψ +KcKuαψ +Kαq +Kuαq −KδUq)2(Kcδψ + δq + δIq)γ
− (Kcψ + q)Kbβδq
(KKcαψ +KcKuαψ +Kαq +Kuαq −KδUq)(Kcδψ + δq + δIq)γ
Γ4 = KK
2
cα
2δIψ
2 +K2cKuα
2δIψ
2 +K2cKuαδδUψ
2 + 2KKcα
2δIψq
+ 2KcKuα
2δIψq + 2KcKuαδδUψq − 2KKcαδIδUψq +Kα2δIq2
+Kuα
2δIq
2 +KuαδδUq
2 − 2KαδIδUq2 +KδIδ2Uq2.
D.2. Elasticity indices of endemic equilibrium.
Consider a system of differential equations dependent on a parameter p
x′ = f(x, p) (40)
27
where
f(x, p) =


f1(x, p)
f2(x, p)
.
.
.
fn(x, p)


, x =


x1
x2
.
.
.
xn


.
At equilibrium point x∗ = x∗(p) satisfies f(x∗(p), p) = 0. Differentiating with
respect to p, one obtains
∂f
∂x1
(x∗(p), p)x′1(p) +
∂f
∂x2
(x∗(p), p)x′2(p) + · · ·+
∂f
∂xn
(x∗(p), p)x′n(p) +
∂
∂p
(x∗(p), p) = 0.
This implies that

∂f1
∂x1
∂f1
∂x1
. . . ∂f1∂xn
∂f2
∂x2
∂f2
∂x2
. . . ∂f2∂xn
. . . . . .
. . . . . .
. . . . . .
∂f1
∂xn
∂fn
∂x2
. . . ∂fn∂xn




x′1(p)
x′2(p)
.
.
.
x′n(p)


= −


∂f1
∂p
∂f2
∂p
.
.
.
∂fn
∂p




x′1(p)
x′2(p)
.
.
.
x′n(p)


= −J−1x∗p


∂f1
∂p
∂f2
∂p
.
.
.
∂fn
∂p


.
Multiplying both sides with the diagonal matrix, diag(p/x∗i ), matrix


p
x∗
1
. . .
p
x∗n




x′1(p)
x′2(p)
.
.
.
x′n(p)


= −


p
x∗
1
. . .
p
x∗n

J−1


∂f1
∂p
∂f2
∂p
.
.
.
∂fn
∂p


.
The sensitivity indices of the steady state variables at equilibrium x∗i with respect
to a parameter p are therefore given by

Γ
x∗
1
p
Γ
x∗
2
p
.
.
.
Γ
x∗n
p


= −KJ−1∂f
∂p
(x∗(p), p) . (41)
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